Free Trial

AstraZeneca (AZN) Competitors

AstraZeneca logo
£106.18 +138.00 (+1.32%)
(As of 12/5/2024 ET)

AZN vs. GSK, SOPH, HCM, GRI, ITH, INDV, SLS, ERGO, BMY, and SLN

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include GSK (GSK), Sophos Group plc (SOPH.L) (SOPH), HUTCHMED (HCM), Grainger (GRI), Ithaca Energy (ITH), Indivior (INDV), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Bloomsbury Publishing (BMY), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry.

AstraZeneca vs.

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership, risk and community ranking.

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£49.13B3.35£6.44B£3.153,370.79
GSK£31.45B1.74£4.03B£1.131,187.16

In the previous week, GSK had 2 more articles in the media than AstraZeneca. MarketBeat recorded 3 mentions for GSK and 1 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.00 beat GSK's score of -0.06 indicating that AstraZeneca is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GSK
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

51.0% of AstraZeneca shares are owned by institutional investors. Comparatively, 45.3% of GSK shares are owned by institutional investors. 0.0% of AstraZeneca shares are owned by company insiders. Comparatively, 1.6% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.2%. GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.5%. AstraZeneca pays out 7,428.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 5,309.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

AstraZeneca presently has a consensus target price of £104.12, indicating a potential downside of 1.94%. GSK has a consensus target price of GBX 1,805.83, indicating a potential upside of 34.61%. Given GSK's stronger consensus rating and higher possible upside, analysts plainly believe GSK is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
GSK
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

AstraZeneca received 768 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.70% of users gave AstraZeneca an outperform vote while only 50.42% of users gave GSK an outperform vote.

CompanyUnderperformOutperform
AstraZenecaOutperform Votes
1858
63.70%
Underperform Votes
1059
36.30%
GSKOutperform Votes
1090
50.42%
Underperform Votes
1072
49.58%

AstraZeneca has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

AstraZeneca has a net margin of 13.11% compared to GSK's net margin of 12.83%. GSK's return on equity of 33.30% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca13.11% 16.74% 7.68%
GSK 12.83%33.30%9.56%

Summary

AstraZeneca beats GSK on 11 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£164.58B£164.58B£5.25B£1.51B
Dividend Yield1.97%1.46%5.82%7.35%
P/E Ratio3,370.79842.70123.441,671.12
Price / Sales3.35334.991,272.49355,259.01
Price / Cash38.8938.8942.4134.94
Price / Book4.174.174.712.81
Net Income£6.44B£6.44B£120.28M£155.90M
7 Day Performance0.06%-0.45%0.46%10.00%
1 Month PerformanceN/A-16.60%0.38%4.94%
1 Year Performance4.82%6.44%30.98%102.41%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
1.6135 of 5 stars
£106.18
+1.3%
£104.12
-1.9%
+4.7%£164.58B£49.13B3,370.7983,500
GSK
GSK
3.1653 of 5 stars
GBX 1,341.50
+0.4%
GBX 1,842.50
+37.3%
-6.8%£54.73B£31.45B1,182.5970,212
SOPH
Sophos Group plc (SOPH.L)
N/AGBX 580.40
+1.0%
N/AN/A£2.99B£726.90M341.41520
HCM
HUTCHMED
N/AGBX 280
+4.1%
N/A-5.0%£2.39B£610.81M-6,725.001,760News Coverage
Gap Down
GRI
Grainger
3.0606 of 5 stars
GBX 233
-0.4%
GBX 317.50
+36.3%
-12.5%£1.72B£270.30M8,183.33372High Trading Volume
ITH
Ithaca Energy
N/AGBX 104.20
+0.2%
N/A-28.8%£1.72B£1.91B866.67220Positive News
INDV
Indivior
1.7708 of 5 stars
GBX 878.50
-0.7%
GBX 1,500
+70.7%
-29.7%£1.13B£1.15B-1,075.001,000
SLS
Standard Life UK Smaller Companies Trust
N/AGBX 732
-1.3%
N/AN/A£715.41M£222.48M3.3710
ERGO
Ergomed
N/AGBX 1,346
flat
N/A+0.0%£701.00M£152.09M4,641.386
BMY
Bloomsbury Publishing
1.326 of 5 stars
GBX 668
0.0%
GBX 825
+23.5%
+56.2%£544.02M£342.65M1,702.5634,300Positive News
High Trading Volume
SLN
Silence Therapeutics
N/AGBX 535
-0.9%
N/A+0.0%£480.35M£11.35M-11.01100High Trading Volume

Related Companies and Tools


This page (LON:AZN) was last updated on 12/6/2024 by MarketBeat.com Staff
From Our Partners